Type 1 Brugada ECG Pattern Mimicking Acute Coronary Syndrome in a Patient With Multiple Potential Acquired Contributors: A Case Report Authors: Ghadeer Doman Published: 2026 ABSTRACT ABSTRACTA Type 1 Brugada ECG pattern may mimic acute coronary syndrome. Careful assessment of cardiac biomarkers, electrolyte abnormalities, medications, and possible substance exposure is essential. Without follow‐up ECG, provocative testing, or genetic evaluation, the finding should be described cautiously as a Brugada‐pattern ECG rather than confirmed Brugada syndrome or phenocopy.Keywords: acute coronary syndrome mimic, Brugada syndrome, Brugada‐like ECG pattern, COVID‐19, delayed presentation Introduction Brugada syndrome (BS), first described in the early 1990s, is associated with unexplained sudden cardiac death in individuals without structural heart disease [1]. Its prevalence is estimated at 2–5 per 10,000, with higher rates reported in Asian populations, and it typically manifests in adulthood. The mean age of sudden cardiac death in patients with BS is approximately 41 years and above [2]. The characteristic ECG finding—coved‐type ST‐segment elevation in leads V1–V3 (Type I Brugada pattern)—was initially reported by Brugada et al. [1]. A distinction should be made between Brugada syndrome, an isolated Type 1 Brugada ECG pattern, and Brugada phenocopy. Brugada phenocopy generally requires an identifiable reversible condition, normalization of the ECG after correction of that condition, and reasonable exclusion of congenital Brugada syndrome [3, 4]. When these criteria cannot be demonstrated, the neutral term “Type 1 Brugada ECG pattern” is preferred. Brugada‐pattern ECG changes may be triggered by several conditions, including fever, viral illness, electrolyte disturbances, cocaine exposure, and medications such as sodium‐channel blockers, beta‐adrenergic blockers, and antidepressants [5, 6]. In this context, acute COVID‐19 has been associated with various cardiac complications, including myocardial infarction, heart failure, and arrhythmias [7, 8]. However, the association between BS and COVID‐19 remains rarely reported and not fully understood [9, 10, 11, 12]. Some reports suggest a link to febrile states, although this remains inconsistent [3]. We describe a 60‐year‐old Saudi man who presented to the emergency department (ED) with cough, dyspnea, and chest pain and was found to have a Type 1 Brugada ECG pattern during evaluation for possible acute coronary syndrome (ACS). He had a remote history of COVID‐19 8 months earlier; however, he remained afebrile and repeatedly tested negative for SARS‐CoV‐2 during the index admission. Case History A 60‐year‐old Saudi man was brought to the ED by ambulance due to a one‐day history of mild productive cough, severe shortness of breath, and mild chest pain. Upon arrival, his temperature was 36.8°C, heart rate 99 beats per minute, blood pressure 134/70 mmHg, and respiratory rate 27 per minute. Oxygen saturation was 92% on room air, with a patent airway, and supplemental oxygen was administered immediately. During admission, full droplet and contact precautions were implemented due to suspected contagious respiratory infection. On physical examination, generalized coarse rales on auscultation were heard throughout both lungs, while heart sounds were normal. The patient had a prior history of COVID‐19 infection 8 months before this current presentation. His past medical history also included alcohol use disorder, reported intranasal cocaine use, uncontrolled diabetes mellitus, and coronary artery disease. A family member reported that he had abstained from alcohol and cocaine for approximately 2 weeks before admission. However, no urine or serum toxicology testing was performed during the index admission, and the timing of the most recent cocaine exposure could not be independently confirmed. There was no history of smoking, drug allergies, or sudden cardiac death in the family. Methods Recurrent COVID‐19 infection, pneumonia, substance‐related effects, and alcohol withdrawal were considered in the initial differential diagnosis. Laboratory testing demonstrated severe hyponatremia, with a serum sodium concentration of 121 mmol/L, renal dysfunction, pancytopenia, elevated C‐reactive protein, increased liver enzymes, and uncontrolled hyperglycemia (Table 1). The other routinely measured electrolytes were within institutional reference ranges. The patient remained afebrile, and microbiological cultures were negative. Blood gas analysis and a complete serial acid–base profile was not available. Urine or serum toxicology testing was also not obtained; therefore, recent cocaine exposure could not be objectively confirmed. SARS‐CoV‐2 testing returned negative. Chest X‐ray was also performed and revealed pulmonary infiltrates and mild bronchial wall thickening, suggestive of a viral or reactive process (Figure 1). TABLE 1Initial laboratory results, grouped by complete blood count and basic metabolic panel, for the 60‐year‐old male patient during Emergency Department presentation.Laboratory testResultReference range Complete blood count White blood cell count (×1000/μL)2.9 a 4.5–11Hemoglobin (g/dL)9 a 13.5–17.5Hematocrit (%)27 a 41.0–53.0Platelet count (×1000/mm3)100 a 150–450Absolute neutrophil count (×1000/μL)0.5 a 1.8–7.7Absolute lymphocyte count (×1000/μL)1.111.1–4.8 Basic metabolic panel Sodium (mmol/L)121 a 135–145Potassium (mmol/L)4.23.5–5.1Chloride (mmol/L)10098–107Carbon dioxide (mmol/L)2422–29Blood urea nitrogen (mg/dL)157–20Creatinine (mg/dL)1.00.7–1.3Glucose (mg/dL)11070–140Calcium (mg/dL)9.08.6–10.2 Cardiac and inflammatory markers High‐sensitivity cardiac troponin (ng/L)0.2< 19C‐reactive proteinElevatedInstitution‐specific a Values outside the stated reference range. The initial sodium level was 121 mmol/L, consistent with severe hyponatremia. Other basic metabolic panel values were within the stated reference ranges. Serial high‐sensitivity troponin measurements were negative; the displayed troponin value of 0.2 ng/L is within the listed reference range and is not marked abnormal. Toxicology testing was not obtained during this admission. Initial laboratory results, grouped by complete blood count and basic metabolic panel, for the 60‐year‐old male patient during Emergency Department presentation. Values outside the stated reference range. The initial sodium level was 121 mmol/L, consistent with severe hyponatremia. Other basic metabolic panel values were within the stated reference ranges. Serial high‐sensitivity troponin measurements were negative; the displayed troponin value of 0.2 ng/L is within the listed reference range and is not marked abnormal. Toxicology testing was not obtained during this admission. A chest X‐ray (Anterior–posterior) of a 60‐year‐old male patient with Brugada‐like pattern shows pulmonary infiltrates with mild bronchial wall thickening. Given the negative COVID‐19 results, supportive management with intravenous fluids and antibiotics was initiated. Reverse Transcriptase‐Polymerase Chain Reaction (RT‐PCR) from nasal and throat swabs was also inconclusive the following day, confirming no active COVID‐19 infection. The patient started immediately on ceftriaxone 1 g intravenously once daily and azithromycin 500 mg intravenously once daily. After admission, antimicrobial therapy was broadened to meropenem 1 g intravenously three times daily, and vancomycin was initiated with a 30 mg/kg intravenous loading dose. These medications were administered as empiric treatment for suspected bacterial pneumonia. Hydroxychloroquine and intravenous immunoglobulin were not administered during the index admission. During the ED evaluation, ACS was suspected because the patient reported acute chest pain and had known coronary artery disease. Therefore, a 12‐lead electrocardiogram (ECG) and serial cardiac biomarkers were also obtained. ECG showed sinus rhythm with coved ST‐segment elevation in leads V1–V3, consistent with a Type 1 Brugada ECG pattern (Figure 2). The tracing was recorded at 25 mm/s and 10 mm/mV. Repeat ECGs obtained at 45 min and 2 h showed persistence of the pattern. The ECGs were reviewed by the cardiology team, who considered ACS unlikely in view of the negative serial high‐sensitivity troponins (Table 1). Additionally, bedside transthoracic echocardiography (TTE) was also performed and demonstrated normal ejection fraction and preserved left ventricular systolic function. Twelve‐lead electrocardiogram (ECG) obtained during evaluation of chest pain, recorded at a paper speed of 25 mm/s and voltage gain of 10 mm/mV. The tracing shows sinus rhythm with coved ST‐segment elevation in leads V1–V3, consistent with a Type 1 Brugada ECG pattern. Conclusion The patient was counseled regarding prompt treatment of fever and avoidance of medications known to aggravate Brugada‐pattern ECG changes. The electronic medical record referenced a previous normal ECG, but the original tracing was unavailable for review. No ECG obtained after correction of the metabolic abnormalities, at discharge, or during outpatient follow‐up was available. The patient was monitored until his condition stabilized and was discharged after 2 days with a plan for cardiology follow‐up. Discussion BS is an inherited arrhythmogenic disorder characterized by a Type 1 ECG pattern in the right precordial leads and an increased risk of ventricular arrhythmia and sudden cardiac death [1]. Contemporary guidance emphasizes that diagnosis and risk assessment should integrate the ECG findings with the clinical presentation, including documented ventricular arrhythmia, arrhythmic syncope, family history, and the results of appropriate electrophysiological or genetic evaluation [2]. Brugada phenocopy, by contrast, requires an identifiable reversible condition, normalization of the ECG after correction of that condition, and reasonable exclusion of congenital Brugada syndrome [3, 4]. In the present case, no post‐correction or follow‐up ECG was available to demonstrate normalization, and sodium‐channel blocker provocation, electrophysiological assessment, and genetic testing were not performed. Therefore, the finding is most appropriately classified as a Type 1 Brugada ECG pattern of uncertain etiology rather than confirmed BS or Brugada phenocopy. In our case, serial ECGs demonstrated a persistent Type 1 Brugada ECG pattern with coved ST‐segment elevation in leads V1–V3. ACS was considered because the patient presented with chest pain and had known coronary artery disease. However, serial high‐sensitivity troponin measurements remained negative, repeat ECGs did not show documented evolving ischemic changes, TTE demonstrated preserved left ventricular systolic function, and cardiology considered ACS unlikely. Several acquired factors were more temporally plausible than the remote COVID‐19 infection, including severe hyponatremia, renal dysfunction, acute systemic illness, reported cocaine exposure, possible alcohol withdrawal, and medications administered during admission. Cocaine‐related sodium‐channel blockade and metabolic or electrolyte disturbances have been associated with transient Brugada‐pattern ECG changes [13]. However, recent cocaine exposure was not confirmed by toxicology testing, complete acid–base data were unavailable, and no post‐correction or follow‐up ECG documented normalization. Therefore, none of these factors can be established as the definitive cause, and the available findings do not fulfill the criteria for confirmed Brugada phenocopy. Brugada‐pattern ECG changes have been reported during acute COVID‐19 infection, particularly in association with fever, systemic inflammation, electrolyte disturbances, and medication exposure [14, 15, 16, 17]. In the systematic review by Liu et al., the reported cases occurred during confirmed acute infection, most patients were febrile, and the ECG pattern normalized after clinical recovery in many cases [17]. In contrast, our patient's COVID‐19 infection occurred 8 months earlier, he remained afebrile, and repeated SARS‐CoV‐2 testing during the index admission was negative. Although inflammatory signaling may influence cardiac ion‐channel function and contribute to electrical instability, this represents biological plausibility rather than evidence that remote COVID‐19 caused the ECG finding in this patient [18]. Therefore, the previous COVID‐19 infection should be considered background medical history rather than a demonstrated trigger. In conclusion, a Type 1 Brugada ECG pattern may resemble ACS in patients presenting with chest pain. In this case, serial negative cardiac biomarkers, absence of documented evolving ischemic ECG changes, preserved left ventricular systolic function, and cardiology assessment made acute myocardial infarction less likely. Several possible acquired contributors were present, but no single cause was established, and the remote COVID‐19 infection was not considered a demonstrated trigger. Because ECG normalization was not documented and provocative, electrophysiological, and genetic testing were not performed, the finding should be classified as a Type 1 Brugada ECG pattern of uncertain etiology rather than confirmed BS or Brugada phenocopy. Accurate classification and follow‐up are important because management recommendations for confirmed symptomatic Brugada syndrome cannot be directly applied to an incompletely classified ECG pattern. Limitation Electrocardiographic documentation was limited. Although the available ECG showed standard calibration and was reviewed by cardiology, the acquisition date/time, formal PR, QRS, QT/QTc, and J‐point measurements were unavailable. Additional limitations included the absence of toxicology testing, blood gas analysis, complete serial metabolic data, and a post‐correction or follow‐up ECG. The medication‐to‐ECG chronology was also not fully documented. Therefore, the specific acquired trigger for the Type 1 Brugada ECG pattern could not be determined. Follow‐up data were limited. No discharge or outpatient ECG was available to determine whether the Type 1 Brugada ECG pattern resolved. In addition, several laboratory abnormalities were not repeated at the time of ECG onset, limiting assessment of their temporal relationship with the ECG pattern. Author Contributions Ghadeer Doman: conceptualization, investigation, methodology, formal analysis, writing – original draft, writing – review and editing. Funding The author has nothing to report. Ethics Statement Ethical approval for this case report was waived from the biomedical ethical committee at King Abdulaziz Jeddah, Saudi Arabia, due to the nature of the study. Consent Written informed consent was obtained from the patient. Conflicts of Interest The author declares no conflicts of interest. Acknowledgments The author has nothing to report. Data Availability Statement The datasets generated and/or analyzed during the current study are available from the corresponding author [G.D.] upon reasonable request. References Associated Data Data Availability Statement The datasets generated and/or analyzed during the current study are available from the corresponding author [G.D.] upon reasonable request.